What is the minimum effective dose of trazodone required for disease-modifying effects in dementia?

INVESTIGATING

The study found trazodone prescribed at doses less than half that predicted to be disease-modifying, but the actual therapeutic threshold remains undefined. This dosing uncertainty prevents proper evaluation of trazodone's neuroprotective potential in clinical settings. Gap type: open_question Source paper: Trazodone and patient outcomes in dementia-Limitations of naturalistic cohort data. (2022, International journal of geriatric psychiatry, PMID:35921312)

Priority: 0.87 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What is the minimum effective dose of trazodone required for disease-modifying effects in dementia? is a 0.87 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: investigating.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What is the minimum effective dose of trazodone required for disease-modifying effects in dementia? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
2
Debates
0.82
Avg Quality
30%
Resolution
0
Mechanistic Families
Gap Resolution Progress30%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed
🎭 What is the minimum effective dose of trazodone required for q=1.00 2026-04-26T16:04
🎭 What is the minimum effective dose of trazodone required for q=0.64 2026-04-25T17:45
update on knowledge_gap by None 2026-04-22T19:29
update on knowledge_gap by None 2026-04-22T14:14
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps